CN1051313C - 5－芳基吲哚衍生物及其用途、含有它们的药物组合物以及制备它们的中间体 - Google Patents

5－芳基吲哚衍生物及其用途、含有它们的药物组合物以及制备它们的中间体 Download PDF

Info

Publication number
CN1051313C
CN1051313C CN93120716A CN93120716A CN1051313C CN 1051313 C CN1051313 C CN 1051313C CN 93120716 A CN93120716 A CN 93120716A CN 93120716 A CN93120716 A CN 93120716A CN 1051313 C CN1051313 C CN 1051313C
Authority
CN
China
Prior art keywords
ylmethyl
indol
indoles
methylpyrrolidin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN93120716A
Other languages
English (en)
Chinese (zh)
Other versions
CN1094727A (zh
Inventor
J·E·梅卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of CN1094727A publication Critical patent/CN1094727A/zh
Application granted granted Critical
Publication of CN1051313C publication Critical patent/CN1051313C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CN93120716A 1992-11-02 1993-11-01 5－芳基吲哚衍生物及其用途、含有它们的药物组合物以及制备它们的中间体 Expired - Fee Related CN1051313C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97075892A 1992-11-02 1992-11-02
US970,758 1992-11-02

Publications (2)

Publication Number Publication Date
CN1094727A CN1094727A (zh) 1994-11-09
CN1051313C true CN1051313C (zh) 2000-04-12

Family

ID=25517470

Family Applications (1)

Application Number Title Priority Date Filing Date
CN93120716A Expired - Fee Related CN1051313C (zh) 1992-11-02 1993-11-01 5－芳基吲哚衍生物及其用途、含有它们的药物组合物以及制备它们的中间体

Country Status (27)

Country Link
US (1) US5886008A (enExample)
EP (2) EP0666858B1 (enExample)
JP (1) JP2788551B2 (enExample)
KR (1) KR0163371B1 (enExample)
CN (1) CN1051313C (enExample)
AT (1) ATE202102T1 (enExample)
AU (1) AU685066B2 (enExample)
BR (1) BR9307348A (enExample)
CA (2) CA2340999C (enExample)
CZ (1) CZ283001B6 (enExample)
DE (1) DE69330351T2 (enExample)
DK (1) DK0666858T3 (enExample)
EG (1) EG20396A (enExample)
ES (1) ES2157224T3 (enExample)
FI (2) FI111257B (enExample)
GR (1) GR3036579T3 (enExample)
HU (1) HU222235B1 (enExample)
IL (1) IL107386A (enExample)
MY (1) MY109696A (enExample)
NO (1) NO309652B1 (enExample)
NZ (1) NZ257059A (enExample)
PL (1) PL176091B1 (enExample)
PT (1) PT666858E (enExample)
RU (1) RU2134266C1 (enExample)
TW (1) TW251284B (enExample)
WO (1) WO1994010171A1 (enExample)
ZA (1) ZA938137B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107835814A (zh) * 2015-04-29 2018-03-23 詹森药业有限公司 氮杂苯并咪唑及其作为ampa受体调节剂的用途

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
CZ59996A3 (en) * 1993-08-31 1996-06-12 Pfizer 5-arylindole derivatives per se and for treating diseases, intermediates for their preparation and pharmaceutical compositions based thereon
AU685881B2 (en) * 1994-02-10 1998-01-29 Pfizer Inc. 5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists
GB9420529D0 (en) 1994-10-12 1994-11-30 Pfizer Ltd Indoles
NZ305166A (en) * 1995-03-20 1998-12-23 Lilly Co Eli 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles; preparation and medicaments
WO1997013512A1 (en) * 1995-10-10 1997-04-17 Eli Lilly And Company N-[2-substituted-3-(2-aminoethyl)-1h-indol-5-yl]-amides: new 5-ht1f agonists
EP0994877A1 (en) 1997-07-03 2000-04-26 Du Pont Pharmaceuticals Company Imidazopyrimidines and imidazopyridines for the treatment of neurological disorders
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
US6353008B1 (en) * 1998-06-30 2002-03-05 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6365589B1 (en) 1998-07-02 2002-04-02 Bristol-Myers Squibb Pharma Company Imidazo-pyridines, -pyridazines, and -triazines as corticotropin releasing factor antagonists
GB9819035D0 (en) * 1998-09-01 1998-10-28 Cerebrus Res Ltd Chemical compounds VII
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
US7399764B2 (en) 2002-10-30 2008-07-15 Merck & Co., Inc. Inhibitors of Akt activity
US20040102360A1 (en) * 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
US7332508B2 (en) 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7638530B2 (en) 2003-04-24 2009-12-29 Merck & Co., Inc. Inhibitors of Akt activity
DE10337184A1 (de) 2003-08-13 2005-03-10 Gruenenthal Gmbh Substituierte 3-Pyrrolidin-Indol-Derivate
US7442709B2 (en) * 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
RU2006108799A (ru) * 2003-08-21 2006-07-27 Оси Фармасьютикалз, Инк. (Us) N3-замещенные имидазопиридиновые ингибиторы c-kit
ES2544477T3 (es) 2003-10-03 2015-08-31 3M Innovative Properties Company Imidazoquinolinas sustituidas con alcoxi
RU2409576C2 (ru) 2003-11-25 2011-01-20 3М Инновейтив Пропертиз Компани Системы, содержащие имидазольное кольцо с заместителями, и способы их получения
DE102004014304A1 (de) * 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
BRPI0709077A2 (pt) * 2006-03-22 2012-04-10 Janssen Pharmaceutica Nv derivados de alquilaminas cìclicas como inibidores da interação entre mdm2 e p53
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
JP6433482B2 (ja) 2013-03-15 2018-12-05 エージンバイオ， インコーポレイテッド 認知機能を改善するための方法および組成物
CA2984290C (en) 2015-04-29 2022-03-01 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as ampa receptor modulators
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
JP6800885B2 (ja) 2015-04-29 2020-12-16 ヤンセン ファーマシューティカ エヌ．ベー． イミダゾピラジン及びピラゾロピリミジン、並びにａｍｐａ受容体調節物質としてのこれらの使用
AU2016268096B2 (en) 2015-05-22 2021-04-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
WO2017076842A1 (en) 2015-11-06 2017-05-11 F. Hoffmann-La Roche Ag Indolin-2-one derivatives
JP6857651B2 (ja) 2015-11-06 2021-04-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｃｎｓ疾患の処置に有用なインドリン−２−オン誘導体
CA3002489C (en) 2015-11-06 2023-11-07 F.Hoffmann-La Roche Ag Indolin-2-one derivatives
CN108349942B (zh) 2015-11-06 2021-03-30 豪夫迈·罗氏有限公司 用于治疗cns和相关疾病的二氢吲哚-2-酮衍生物
CN111822047B (zh) * 2020-07-17 2022-05-27 曲阜师范大学 一种磁性介孔聚合离子液体负载催化合成吲哚类衍生物的方法
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
WO2025104490A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313397A1 (en) * 1987-10-23 1989-04-26 The Wellcome Foundation Limited Therapeutic heterocyclic compounds
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA795239B (en) * 1978-10-12 1980-11-26 Glaxo Group Ltd Heterocyclic compounds
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
US4983622A (en) * 1984-02-06 1991-01-08 Eli Lilly And Company 6-substituted-4-dialkylaminotetrahydrobenz(c,d)indoles
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds
IL96891A0 (en) * 1990-01-17 1992-03-29 Merck Sharp & Dohme Indole-substituted five-membered heteroaromatic compounds,their preparation and pharmaceutical compositions containing them
US5340838A (en) * 1990-05-04 1994-08-23 Eli Lilly And Company Method of inhibiting gastric acid secretion with 2-phenylcyclopropylamines
CA2042295A1 (fr) * 1990-05-15 1991-11-16 Jacques Chauveau Derives de mediateurs endogenes, leurs sels, procede de preparation, applications, et compositions les renfermant
EP0636623B1 (en) * 1990-06-07 2001-08-16 AstraZeneca AB Indole derivatives as 5-HT1- like agonists
DK158590D0 (da) * 1990-07-02 1990-07-02 Lundbeck & Co As H Indolderivater
SK278998B6 (sk) * 1991-02-01 1998-05-06 Merck Sharp & Dohme Limited Deriváty imidazolu, triazolu a tetrazolu, spôsob i
FR2672602B1 (fr) * 1991-02-12 1993-06-04 Centre Nat Rech Scient Composes derives des beta-carbolines ligands du recepteur des benzodiazepines ayant un effet agoniste inverse et antagoniste vis-a-vis des benzodiazepines et medicaments les contenant.
US5229401A (en) * 1991-09-23 1993-07-20 Hoechst-Roussel Pharmaceuticals Incorporated Substituted pyridinylamino benzo[b]thiophene compounds
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
US5378846A (en) * 1993-06-11 1995-01-03 Russian-American Institute For New Drug Development 1,2,3,4-tetrahydropyrrolo-[1,2-a]-pyrazine derivatives

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0313397A1 (en) * 1987-10-23 1989-04-26 The Wellcome Foundation Limited Therapeutic heterocyclic compounds
WO1992006973A1 (en) * 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107835814A (zh) * 2015-04-29 2018-03-23 詹森药业有限公司 氮杂苯并咪唑及其作为ampa受体调节剂的用途
US12304908B2 (en) 2015-04-29 2025-05-20 Rapport Therapeutics, Inc. Azabenzimidazoles and their use as AMPA receptor modulators

Also Published As

Publication number Publication date
CN1094727A (zh) 1994-11-09
CZ110895A3 (en) 1995-11-15
JPH07508759A (ja) 1995-09-28
AU685066B2 (en) 1998-01-15
ES2157224T3 (es) 2001-08-16
HUT66011A (en) 1994-08-29
ZA938137B (en) 1995-05-02
CA2340999A1 (en) 1994-05-11
NO951633L (no) 1995-04-28
EG20396A (en) 1999-02-28
KR950704313A (ko) 1995-11-17
DE69330351D1 (de) 2001-07-19
EP0666858A1 (en) 1995-08-16
NO309652B1 (no) 2001-03-05
WO1994010171A1 (en) 1994-05-11
US5886008A (en) 1999-03-23
FI111257B (fi) 2003-06-30
PL308669A1 (en) 1995-08-21
JP2788551B2 (ja) 1998-08-20
CZ283001B6 (cs) 1997-12-17
CA2148380A1 (en) 1994-05-11
GR3036579T3 (en) 2001-12-31
CA2148380C (en) 2001-08-14
DK0666858T3 (da) 2001-08-27
ATE202102T1 (de) 2001-06-15
HU222235B1 (hu) 2003-05-28
EP1094064A1 (en) 2001-04-25
NO951633D0 (no) 1995-04-28
PT666858E (pt) 2001-09-28
MY109696A (en) 1997-04-30
EP0666858B1 (en) 2001-06-13
AU5329494A (en) 1994-05-24
DE69330351T2 (de) 2001-09-20
KR0163371B1 (ko) 1998-12-01
FI20002505L (fi) 2000-11-15
RU95109927A (ru) 1997-01-10
IL107386A (en) 1999-03-12
FI934825L (fi) 1994-05-03
FI934825A0 (fi) 1993-11-01
PL176091B1 (pl) 1999-04-30
FI20002505A7 (fi) 2000-11-15
IL107386A0 (en) 1994-01-25
TW251284B (enExample) 1995-07-11
NZ257059A (en) 1997-07-27
RU2134266C1 (ru) 1999-08-10
CA2340999C (en) 2005-01-04
BR9307348A (pt) 1999-05-11

Similar Documents

Publication Publication Date Title
CN1051313C (zh) 5－芳基吲哚衍生物及其用途、含有它们的药物组合物以及制备它们的中间体
CN1045294C (zh) 吲哚衍生物的制备方法
CN1165537C (zh) 作为5-ht2c兴奋剂的吡咯并吲哚、吡啶并吲哚和氮杂�并吲哚
CN1061341C (zh) 1－氨基乙基吲哚衍生物
CN1064362C (zh) 嘧啶并[5,4－d]嘧啶,含这种化合物的药物,其用途和其制备方法
CN1260225C (zh) 四氢吡啶基或哌啶基杂环衍生物
CN1135982C (zh) 含n-酰基-2,3-苯并二氮杂�衍生物的药物组合物的制备方法
CN1209129A (zh) 促性腺激素释放激素的拮抗药
CN1085556A (zh) 抗偏头痛的吲哚-3-基烷基哌嗪的4-嘧啶基和吡啶基衍生物
CN1212695A (zh) 4－氨基－嘧啶衍生物,含该化合物的药物制剂,其用途及其制造方法
CN1118598A (zh) 吡咯并吡啶衍生物
CN1319090A (zh) 新的取代的二氢吲哚酮、它们的制备方法和它们作为药物的用途
CN1713910A (zh) 作为p38激酶抑制剂的氮杂吲哚衍生物
CN1668590A (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚或－吲唑衍生物
CN1656082A (zh) 蛋白激酶抑制剂
CN1671696A (zh) 激酶抑制剂
CN1617869A (zh) 作为尿压素ⅱ受体拮抗剂的4－(哌啶基－吡咯烷基－烷基－脲基)－喹啉类化合物
CN1454211A (zh) 作为Xa因子抑制剂的含氮杂双环化合物
CN1250542C (zh) 具有抗肿瘤活性的2－(1h－吲哚－3－基)－2－氧代－乙酰胺
CN1499972A (zh) 用作促肾上腺皮质激素释放因子抑制剂的咪唑基衍生物
JP2025510074A (ja) Ｐｒｏｔａｃにおけるデグロンとしての２，４－ジオキソテトラヒドロピリミジニル誘導体
CN1620290A (zh) 作为5－羟色胺－6配体的吲哚基烷基胺衍生物
CN87103504A (zh) 杂环羧酰胺
CN1092765A (zh) 新的色胺类似物及其制备方法与用途
CN1934083A (zh) 作为肾素抑制剂用于治疗高血压的5－氨基－4－羟基－7－(1h－吲哚基甲基)－8－甲基壬酰胺衍生物

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee